ABCureD is a multi-awarded health-tech start-up and the first biomedical spin-off of Democritus University of Thrace (DUTH). The company focuses on advancing precision medicine and create value through innovative biomarker discovery and translational research.
By bridging academic excellence with entrepreneurial innovation, ABCureD develops novel diagnostic and therapeutic approaches for complex diseases, with a particular focus on metabolic disorders such as diabetes. LPancreas is our first-in-kind new gen precision diagnosis product, built to transform diabetes care.
Greek biotech spin-off (DUTH) with a patented biomarker that directly measures β-cell decline from blood. Seeking to join a consortium.
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Academic pharmacology lab + hospital + spin-off offering trial design, protocol support and patient recruitment, plus a patented liquid-biopsy biomarker of β-cell decline as an exploratory pharmacodynamic endpoint for intervention clinical trials.
Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases